Expanding to Spain: A Thriving Market for Cell & Gene Research

Expanding into Spain’s dynamic Cell & Gene research hub bolsters our global presence in clinical research communities.

Over the past few years, CRYOPDP has actively acquired companies with innovative technologies and principles aligned with ours, enhancing our capacity to deliver life-saving goods worldwide.

CRYOPDP recently acquired Polar Expres, a leading clinical, cell, and gene biopharma logistics provider based in Spain. Polar Expres serves customers in both the public and private sectors.

Polar Expres’s expertise in clinical, cell, gene, and biomedical logistics, along with its unique services, enables CRYOPDP to expand its footprint in one of the top geographical markets in the Clinical Research area, especially in the dynamic and growing Cell & Gene sector.

This acquisition allows CRYOPDP further to broaden its temperature-controlled logistics and supply chain solutions, meeting the demands of the life science and healthcare communities.


By integrating the Polar Expres team into CRYOPDP’s network in Spain, we enhance our capacity to deliver life-saving goods worldwide.

“Polar Express represents a significant opportunity for CRYOPDP in the south of Europe and Europe. With a solid and well-established reputation, Polar Express will allow us to reinforce our position in the Biopharma and Cell and gene market, expanding our opportunities among Clinical Trials communities”, said Cedric Picaud, CRYOPDP’s Chief Executive Officer.

Jerrell Shelton, CEO of Cryoport, stated, “The acquisition of Polar Expres will expand our coverage in Europe. It will enable us to provide end-to-end solutions to global and local customers in Spain. Spain is a highly strategic area for pharma/biopharma clinical trials. It also sees a growing number of cell & gene activities. This tactical acquisition will strategically impact CRYOPDP. Requests for local, on-the-ground operations in Spain continue from many clients and potential new ones. We are confident that Polar Expres is now part of our growing CRYOPDP operations. This acquisition will provide us with additional growth in the EMEA region.”



As one of the top leaders in its field, CRYOPDP aims to improve global health. They provide innovative, temperature-controlled logistics solutions to the Clinical Research and Cell and Gene Therapy communities. With facilities in 15 countries and operations in over 150 countries, CRYOPDP is dedicated to enhancing worldwide healthcare.

About Cryoport, Inc.:

Cryoport, Inc. (Nasdaq: CYRX) transforms life sciences logistics with its temperature-controlled supply chain solutions platform. It serves the Biopharma, Reproductive Medicine, and Animal Health markets, aiming to support life and health globally. Cryoport relies on advanced technologies and a global network of experts to deliver reliable solutions. Their mission is to advance the life sciences industry.